New paradigms in hepatitis B management: only diamonds are forever.
نویسندگان
چکیده
INTRODUCTION The hepatitis B virus (HBV) causes chronic hepatitis B (CHB) in ∼350 million people worldwide who have an increased risk of end-stage liver disease and/or hepatocellular carcinoma. SOURCES OF DATA Several peer-reviewed papers featuring new approaches to anti-HBV management. Additionally, we also reviewed recent abstract presentations at international congresses. AREAS OF AGREEMENT There has been great progress in CHB therapy with the development of standard and pegylated interferon (i.e. PEG-IFN) as well as nucleos/tide analogs (NAs). IFN has both antiviral and immunomodulatory effects and through immune-mediated destruction of infected hepatocytes offers the possibility of finite therapy. However, this 'killing for a cure' antiviral strategy may not be tolerated in many, especially in cirrhotic patients. NAs inhibit viral reverse transcriptase, have few side effects and prevent liver disease progression, but cannot offer a cure as they have little effect on the resilient HBV covalently closed circular DNA (cccDNA) intermediate. Moreover, NAs such as tenofovir and entecavir offer a high genetic barrier to resistance, but are expensive and not readily available in many global regions. GROWING POINTS Despite significant treatment advances, there is increased recognition of the need for improved anti-HBV treatments, and new virologic tests for monitoring treatment response. AREAS OF CONTROVERSY The role of quantitative hepatitis B surface antigen, intrahepatic cccDNA levels and viral genotype in selecting treatment candidates and refining NA stopping rules. AREAS TIMELY FOR DEVELOPING NEW RESEARCH Potential new therapies include viral entry inhibitors, RNA interference technologies (i.e. RNAi) and small molecules that modulate cccDNA transcription, as well as novel immunomodulatory therapies to boost HBV-specific T cell responses. The ultimate goal of new tests and anti-HBV therapies is to reduce the burden and expense of life-long CHB treatment, as 'only diamonds are forever'.
منابع مشابه
Hepatitis B sero-markers evaluation in People born in 1989 in Zabol
Background: Hepatitis B virus is known as one of the most common pathogen in the world. 350 million people are chronic carrier in the world and more than 3/4 hepatitis B virus infection are in Middle East and Africa. Various statistics of this infection has been reported in Iran. Since vaccination plan of 1989 born not only in Zabol but through Iran, will be performed and there is no exact info...
متن کاملهپاتیت B قابل پیشگیری و درمان است
Viral hepatitis is one of five infectional factors cause early death in all over the world. Every day at least one million people die because of viral hepatitis. Six hepatitis viruses have been known until now. They are A, B, C, D, E, G, and it is probable that at least two other kinds i.e. F, and H, will be known soon. Only hepatitis B is a DNA virus, and the others are RNA viruses. All viruse...
متن کاملUrban Growth Carriers; An Alternative Policy for Urban Growth Management in Iran
Like other developing countries, Iranian cities are growing and expanding physically at a high speed. For about five decades, the only policy of the urban development plans in the field of urban growth management has been definition of the Urban Growth Boundary (U.G.B.) which is still used without any major modifications.Despite the slight evidences indicating the ineffectiveness of the current...
متن کاملOn the way to mass-scale production of perfect bulk diamonds.
D iamonds are hard. Humans have known that for ages. This hardness encompasses not only mechanical hardness, but also chemical, electrical, optical, and structural hardness (1). Diamonds are hard to cut, and shaping them requires a complex technology. Diamonds are chemically inert and, because of this, they are not processed chemically. Diamonds are resistant to electrical fields and, as an ele...
متن کاملSignificance of Hepatitis B Core Antibody as the Only Marker of Hepatitis B Virus Infection in High Risk Patients
Background and Objective: Presence of hepatitis B core antibody (anti-HBc) in the absence of hepatitis B surface antigen (HBsAg) and hepatitis B surface antibody (anti-HBs) is defined, as isolated anti-HBc. little is known about the clinical significance of the isolated anti-HBc in hepatitis B virus (HBV) infections. The aim of this study was to assess the significance of anti-HBc as the onl...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- British medical bulletin
دوره 116 شماره
صفحات -
تاریخ انتشار 2015